The relatively low incidences of such mutations in H and N cancer, as well as mutations in KRAS, BRAF, and HER2, indicate the necessity for analysis of much larger patient populations together with investigation of alternative molecular pathways and mechanisms to identify predictive or prognostic markers. This evidence concerns the gene KRAS and cancer.